Related Experiment Video
Updated: Aug 19, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Post-COVID mRNA vaccine myocarditis in children: report of two cases
Ahmed Shamekh1, Colin Powell2, Abdusamea Ashabani3
1Paediatric Emergency, Sidra Medicine, Doha, Ad Dawhah, Qatar ashamekh@hotmail.com.
Insights
The Pfizer-BioNTech COVID-19 vaccine is safe and effective for adolescents. However, rare cases of myocarditis have been reported after the second dose in young males.
Area of Science:
- Cardiology
- Vaccinology
- Pediatrics
Background:
- The SARS-COV-2 pandemic necessitated rapid vaccine development.
- The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) received authorization for individuals aged 12 and above in May 2021.
- While generally safe and effective, post-vaccination adverse events require ongoing monitoring.
Abstract:
The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.
More Related Videos
Related Concept Videos
Myocarditis I: Introduction
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Pericarditis I: Introduction

